NCT04936529 2026-03-13A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With NeuroblastomaMemorial Sloan Kettering Cancer CenterPhase 2 Recruiting286 enrolled
NCT03363373 2026-02-19Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone MarrowY-mAbs TherapeuticsPhase 2 Recruiting122 enrolled 2 FDA